Appeal No. 1999-1229
Application 08/543,975
consolidating the appeals. The issues raised in each appeal have been considered only
on the basis of the evidence provided therein and its relevancy to the claims in the involved
application.
Claims 1 and 30 are illustrative of the claims in the present appeal and read as
follows:
1. A solid, orally administrable composition for the enzymatic hydrolysis of
lactose comprising:
a therapeutic effective amount of a first, active lactase having a first optimum
pH range; and
a therapeutic effective amount of a second, active lactase having a second
optimum pH range, wherein said first and second optimum pH ranges being
different; and
a solid pharmaceutically acceptable carrier.
30. A solid, oral dosage form for treating or controlling the symptoms of lactose
intolerance in humans, comprising:
an amount of lactase derived from the fungi selected from the group
consisting of Aspergillus oryzae and Aspergillus niger equivalent to about 3000 to
about 6000 FCC Lac U;
an amount of enterically coated lactase derived from Kluyveromyces lactis
equivalent to about 7000 to about 35,000 neutral lactase units; and
a solid, pharmaceutically acceptable carrier.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007